Outcome of Platelet Rich Plasma in ICSI Patients, a Randomized Controlled

Status Not yet recruiting

Clinical Trial Summary

2 groups randomized to PRP injectioninto uterine cavity at mock embryo transfer, and a control group with only mock embryo transfer.

Clinical Trial Description

Participants are allocated in two groups ( randomized). Study is conducted in Dar El Teb infertility and IVF centre, Egypt. Normoresponder patients (9-15 mature follicles on day of HCG administration) and candidates for fresh embryo transfer are recruited to the study. 788 patients will be randomized on the day of ovum pick up in a 1 to 1 ratio to platelet rich plasma (PRP) group and control group. Patients wee randomized using computer generated randomization list and sequentially numbered sealed envelopes containing allocation information written on a card. The embryologist and doctors responsible for follow up after ovum pick up aew blinded to received treatment. Ovarian stimunlation is achieved by highly purified urinary FSH (Fostimon, IBSA, Switzerland)started on the 2nd or 3rd day of menstruation. The initial dose ranged between 150-300IU/d depending on expected ovarian response and serum E2 level. GnRH antagonist (Cetrotide, Serono international, Geneva, Switzerland) 0.25mgSC/day will be give when the leading follicle is 14mm and continued till day of HCG. 10,000 IU HCG will be given when 3 or more follicles are 18mm on mean diameter. Oocyte retrieval will be performed 34-36 hours after HCG administration. In PRP group, 1 ml autologous PRP prepared from blood of participants and injected under ultrasound guidance inside the uterus while performing the mock embryo transfer. In control group, mock embryo transfer was performed without injecting anything inside the uterus. All participants will receive progesterone vaginal pessaries (Prontogest, Marcyrl, Egypt) 400 mg twicw daily, starting on day of oocyte retrieval till 12weeks gestation or negative pregnancy test. No more than 3 embryos will be transferred2-5 days after oocyte retrival. B HCG levels will be measured in blood 14 days after HCGadministration. Transvaginal ultrasound will be performed 4 weeks after embryo transfer to confirm clinical pregnancy. ;

Study Design

Related Conditions & MeSH terms

Pregnancy Outcome

Clinical Trial Details

NCT number	NCT04434495
Study type	Interventional
Source	Dr. Osman Hospital
Contact	Hisham Gouda, MD
Phone	00201001885885
Email	Sheemer75@gmail.com
Status	Not yet recruiting
Phase	Phase 2
Start date	June 15, 2020
Completion date	April 15, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06313112` - Impact of Food Insecurity on Utilization of Maternal Healthcare Services and Birth Outcomes in Slums in Pune, India
Recruiting	`NCT03242746` - Cervical Morphological Changes on Pregnancy Outcome
Recruiting	`NCT04515134` - Assessment of Follicular Fluid Level of Coenzyme Q10 in Women Undergoing ICSI
Completed	`NCT03740568` - Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes.	N/A
Completed	`NCT05355038` - Effect of Lifestyle Modification on Pregnancy Outcome for GDM	N/A
Recruiting	`NCT05506631` - Foley Balloon Study for Cervical Ripening - Cost Comparison Between Outpatient and Inpatient Cervical Ripening	N/A
Terminated	`NCT03489174` - Routine Pregnancy Screening for Women on Opioid Substitution Therapy	N/A
Completed	`NCT03748576` - A Prospective Randomized Controlled Trial of Mobile Medical Used for Management of Pregnant Women	N/A
Active, not recruiting	`NCT03113331` - The 3D Cohort Study (Design, Develop, Discover)
Active, not recruiting	`NCT03215368` - The Ma'Anshan Birth Cohort (MABC)
Recruiting	`NCT04930276` - Diet-glucose-gut Microbiome Net in Women With GDM	N/A
Enrolling by invitation	`NCT04977466` - NIH Intramural Research Program s Pregnancy Registry Protocol for Subjects and Their Partners
Withdrawn	`NCT05847140` - A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During Pregnancy
Active, not recruiting	`NCT02271490` - Acrosome Reaction Induction Prior to ICSI	N/A
Not yet recruiting	`NCT04434547` - A RCT on the Effect of Platelets Rich Plasma in ICSI Patients With Recurrent Implantation Failure	Phase 2
Completed	`NCT05647538` - Bilateral Uterine Artery Ligation After Intrapartum or Postpartum Hemorrhage on Ovarian Reserve Markers and Pregnancy Outcome
Completed	`NCT00878098` - Study of DDT and Loss of Clinically-Recognized Pregnancies in South Africa
Completed	`NCT01653392` - BioThrax® (Anthrax) Vaccine in Pregnancy Registry
Recruiting	`NCT05733377` - Non-invasive Imaging Technique for the Study of Lordosis in Pregnant Women and Its Relationship to Birth Outcome
Not yet recruiting	`NCT05457335` - 2.Comparison of the Live Birth Rate of PGT Versus Expectant Management in Patients With RPL

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Outcome of Platelet Rich Plasma in ICSI Patients, a Randomized Controlled Trial

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms